NCT07899918Not yet recruiting
Dual-Energy Lattice-Tip Assisted Marshall-Plan Strategy in Redo Persistent Atrial Fibrillation Ablation
Dual-Energy Lattice-Tip Assisted "MArshall-Plan" Strategy Versus Pulmonary Vein Re-Isolation Alone in Redo Persistent Atrial Fibrillation: A Randomized Trial
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This clinical trial will assess the efficacy and safety of a Marshall plan-based ablation strategy without ethanol infusion into the vein of Marshall in patients with persistent atrial fibrillation undergoing repeat ablation with a dual-energy lattice-tip catheter. Eligible participants will be randomized to receive either pulmonary vein re-isolation alone or pulmonary vein re-isolation plus the Marshall plan-based strategy. Patients who are found to have all pulmonary veins already isolated at the time of the procedure, or who are not suitable candidates for the Marshall plan-based approach, will be included in a separate observational cohort.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 234 (estimated)
- First submitted
- 20 Oct 2026
- Start date
- Jan 2027
- Primary completion date
- Feb 2029
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT07899918
What you commit to
- Study type: Interventional
- Planned participants: 234
- From Jan 2027 to the primary completion date, Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous linear ablations in the left atrium beyond the PVI
Other illness
- Acute coronary syndrome or coronary artery bypass surgery within 12 weeks.
- Severe valvular heart disease using the ESC guidelines or congenital heart disease.
- Medical conditions likely to limit survival\<12 months
Other
- Contraindication to oral anticoagulation.
- AF due to a reversible cause.
- Patients who are unable or unwilling to provide informed consent.
- BMI\<18 kg/m2 or BMI\>37 kg/m2
Who the study is looking for
- Clinical indication for re-ablation of persistent atrial fibrillation
- Previous catheter ablation for atrial fibrillation with PVI
- Suitable candidate for catheter ablation according to European Society of Cardiology (ESC) guidelines
- Age ≥18 years.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska University Hospital Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.